Investigating how a fungal protein affects immune responses in oral cells
Candida albicans secreted protease Sap6 engages epithelial protease-activated receptors PAR2 and NLRP3
This study is looking at how a protein from the fungus Candida albicans, called Sap6, affects our immune system in the mouth, and it aims to find new ways to help treat infections caused by this fungus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10428637 on NIH RePORTER |
What this research studies
This research focuses on the role of a specific protein secreted by the fungus Candida albicans, known as Sap6, in triggering immune responses in oral epithelial cells. The study aims to understand how Sap6 interacts with cell surface receptors to influence inflammation and cell signaling. By examining the mechanisms through which Sap6 activates these receptors, researchers hope to uncover new insights into the pathogenicity of Candida albicans and its effects on human health. The findings could lead to novel therapeutic strategies for managing infections caused by this fungus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are prone to Candida infections, particularly those with oral candidiasis or other related conditions.
Not a fit: Patients who do not have any history of fungal infections or those with non-oral related health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage or prevent infections caused by Candida albicans.
How similar studies have performed: Previous research has shown that targeting similar fungal proteins can lead to significant advancements in understanding and treating fungal infections, indicating a promising avenue for this study.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Edgerton, Mira — State University of New York at Buffalo
- Study coordinator: Edgerton, Mira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.